Title:
PHARMACEUTICAL COMPOSITION OF RIP2 INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/099363
Kind Code:
A1
Abstract:
Disclosed are a pharmaceutical composition of a receptor-interacting protein 2 (RIP2) inhibitor in combination with an immune checkpoint inhibitor and use thereof. The present invention provides a pharmaceutical composition comprising an RIP2 inhibitor and an immune checkpoint inhibitor (ICI). Particularly, the present invention provides use of the RIP2 inhibitor in combination with the ICI in the preparation of a medicament for treating and/or preventing tumors. The knockout of the RIP2 or the RIP2 inhibitor has a new application of increasing the sensitivity of tumors to the ICI, i.e., has the effect of enhancing the anti-tumor activity of an ICI medicament. According to the present invention, the anti-tumor activity of an ICI medicament can be enhanced by knocking out the RIP2 or using the RIP2 inhibitor for the first time. After the RIP2 inhibitor and the ICI are jointly used, the proportions of CD3+ cells, CD8+ T cells, γδTCR+ T cells, effector memory T cells, and CD8 effector T cells (IFNγ+ CD8+ T cells, Granzyme B+ CD8+ T cells, TNFα+ CD8+ T cells, and CD107a+ CD8+ T cells) in a tumor microenvironment are up-regulated, and the therapeutic effect of the ICI medicament on tumors is enhanced.
Inventors:
LIU GANG (CN)
MA YAO (CN)
WEI XIDUAN (CN)
MA YAO (CN)
WEI XIDUAN (CN)
Application Number:
PCT/CN2023/130489
Publication Date:
May 16, 2024
Filing Date:
November 08, 2023
Export Citation:
Assignee:
NINGBO COMBIREG PHARMACEUTICAL TECH CO LTD (CN)
International Classes:
A61K45/06; A61K31/415; A61K31/435; A61K31/495; A61K39/395; A61P35/00
Domestic Patent References:
| WO2021202428A1 | 2021-10-07 | |||
| WO2021152165A1 | 2021-08-05 |
Foreign References:
| US20220228222A1 | 2022-07-21 | |||
| CN112638405A | 2021-04-09 | |||
| US20210255168A1 | 2021-08-19 |
Other References:
YANG JAMES CHIH-HSIN, GADGEEL SHIRISH M.; SEQUIST LECIA VANDAM; WU CHIEN-LIANG; PAPADIMITRAKOPOULOU VASSILIKI A.; SU WU-CHOU; FIOR: "Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation", JOURNAL OF THORACIC ONCOLOGY, ELSEVIER, vol. 14, no. 3, 1 March 2019 (2019-03-01), pages 553 - 559, XP093170138, ISSN: 1556-0864, DOI: 10.1016/j.jtho.2018.11.028
ANNA W. CHALMERS ET AL.: "Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long‑Term Follow‑Up", TARGETED ONCOLOGY, vol. 14, 25 July 2019 (2019-07-25), XP036898335, ISSN: 1776-2596, DOI: 10.1007/s11523-019-00658-0
ANNA W. CHALMERS ET AL.: "Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long‑Term Follow‑Up", TARGETED ONCOLOGY, vol. 14, 25 July 2019 (2019-07-25), XP036898335, ISSN: 1776-2596, DOI: 10.1007/s11523-019-00658-0
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: